Clinical Trial

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Study acronym: Drugs-SNPs
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-05-30
critical Primary endpoint(s) modified 2026-05-23
Trial Details
NCT Number NCT05987956
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborators: UnitedHealthcare, Omnicure Clinical Research
Conditions ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Enrollment 600 participants
Start Date 2026-03-18
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-01